Liquid Biopsy Market to Reach $29.8 Billion by 2035, Growing at 15.6% CAGR | NeoGenomics, Thermo Fisher Scientific, QIAGEN Among Key Players

The global liquid biopsy market, valued at USD 7.0 billion in 2025, will grow to USD 8.1 billion in 2026 and reach USD 29.8 billion by 2035, at a compound annual growth rate of 15.6% over the forecast period. This growth reflects a fundamental shift in oncology diagnostics, where non-invasive blood-based testing is rapidly displacing painful, high-risk tissue biopsies across early detection, treatment selection, and post-treatment monitoring applications. With cancer deaths projected to reach 16.3 million annually by 2040, according to the World Health Organization, the clinical and commercial urgency behind liquid biopsy has never been sharper.

To explore the complete findings, request a free sample of the report at https://www.rootsanalysis.com/reports/liquid-biopsy-and-nicd-market/request-sample.html

MARKET OVERVIEW
Liquid biopsy refers to the analysis of blood, plasma, urine, or other bodily fluids to detect genetic mutations and circulating biomarkers shed by tumors. Unlike traditional tissue biopsy, it carries minimal procedural risk, can be repeated over time for ongoing monitoring, and captures tumor heterogeneity across sites, qualities that make it especially valuable for patients with advanced or metastatic disease. The technique has moved well beyond academic interest; over 160 manufacturers are now active in the space, collectively offering more than 350 products either launched or in active development.

The convergence of several forces is accelerating clinical adoption. Regulatory agencies, particularly the U.S. FDA, have approved a growing number of liquid biopsy products for companion diagnostic and screening applications. Research institutions and biopharmaceutical companies are forging partnerships at an accelerating pace, with more than 75% of collaboration deals in the sector signed within the past three years alone. Close to USD 7.3 billion in external funding has flowed into liquid biopsy companies over the past four years, with investors ranging from venture capital firms to large strategic players, confirming that private capital sees the market trajectory as durable.

Recent deals illustrate the momentum. In June 2023, Foundation Medicine signed an agreement with Merck KGaA to develop liquid biopsy companion diagnostic tests for cancer therapies. In September 2025, Myriad Genetics entered a collaboration with SOPHiA GENETICS to advance companion diagnostic solutions for biopharma partners. In July 2025, NeoGenomics launched its NEO PanTracer LBx, a comprehensive genomic profiling test designed for therapy selection, trial matching, and longitudinal monitoring.

KEY GROWTH DRIVERS
Rising Cancer Incidence and the Demand for Non-Invasive Diagnostics Global cancer burden is escalating. The WHO projects roughly 16.3 million cancer-related deaths by 2040, and breast cancer alone accounts for approximately 297,790 new cases annually in the United States. This clinical volume creates sustained demand for faster, safer, and repeatable diagnostic tools. Liquid biopsy meets all three criteria, and its adoption is growing in both hospital and research settings.

Expanding Regulatory Approvals FDA approvals for liquid biopsy products have increased materially over the past several years, giving clinicians confidence in test accuracy and payers a basis for reimbursement. Each new approval broadens the addressable market by opening additional cancer indications or patient populations to non-invasive testing. Regulatory momentum in Asia-Pacific is also building, with several market approvals in Asian markets recorded recently.

Surge in Funding and Venture Investment Close to USD 7.3 billion in investment has entered liquid biopsy companies over four years, primarily through venture rounds. Grail has attracted the largest single pool of funding. In July 2023, MiRXES raised USD 50 million in Series D funding for colorectal cancer and multi-cancer early detection products. In April 2023, Epic Sciences secured USD 24 million in Series G funding for liquid biopsy targeting metastatic breast cancer. This sustained capital deployment is accelerating product development timelines.

Proliferation of Partnerships and Technology Development Agreements More than 75% of all liquid biopsy partnership deals have been executed within the past three years, reflecting a market where technology combinations are driving competitive advantage. Agreements between diagnostic companies and pharmaceutical developers, such as Foundation Medicine with Merck KGaA and Naveris with Mayo Clinic, are moving companion diagnostic applications toward regulatory submission and clinical use at meaningful scale.

Advances in Circulating Biomarker Detection Scientific progress in detecting circulating tumor DNA, extracellular vesicles (exosomes), and cell-free RNA is expanding what liquid biopsy can identify and at what sensitivity levels. The exosome segment, in particular, is forecast to grow at a comparatively higher rate than other biomarker categories, reflecting the scientific community's growing recognition of exosomes as a rich source of diagnostic signal.

MARKET SEGMENTATION
The liquid biopsy market segments across application, circulating biomarker type, target disease indication, sample type, end user, and geography. By application, early cancer diagnosis commands the dominant position, accounting for approximately 60% of market share throughout the 2026 to 2035 forecast window. Patient monitoring and recurrence monitoring account for the remaining share, though both are growing as oncologists increasingly rely on serial liquid biopsy results to track treatment response.

By circulating biomarker, circulating tumor DNA holds the largest segment at 51% of the market, given its direct link to tumor genotyping and treatment selection. The exosome segment is growing at a faster rate and attracts particular research interest for its potential in multi-cancer detection. Blood and plasma account for 97% of all sample types processed, reflecting the practical accessibility of blood draws compared to other bodily fluids. Hospitals hold approximately 80% of the end-user market, with research institutes comprising the remainder. Among techniques, PCR methods capture roughly 60% of the market by type, underpinned by their sensitivity and established laboratory infrastructure.

To request quote of this report, please visit:
https://www.rootsanalysis.com/reports/liquid-biopsy-and-nicd-market/request-quote.html

REGIONAL INSIGHTS
North America leads the global liquid biopsy market with approximately 40% of total market share, a position it holds by virtue of its high cancer incidence rates, a mature regulatory approval pathway through the FDA, and strong insurance coverage frameworks that incentivize clinical adoption of novel diagnostics. The region is also home to the majority of liquid biopsy companies globally, with about 60% of all manufacturers headquartered in the United States, including notable names such as ArcherDX, ClearNote Health, Personal Genome Diagnostics, Sysmex Inostics, and Helio Genomics. The collaborative infrastructure between academic medical centers and commercial diagnostics companies in the U.S. gives North America a durable structural advantage.

Europe holds the second-largest share, with companies based across Belgium, Spain, Italy, and Sweden contributing to a competitive product environment. The Asia-Pacific region, however, is the one to watch for growth investors. It is forecast to post the highest CAGR of all regions through 2035, driven by rising adoption of liquid biopsy technologies, expanding regulatory approvals across major markets such as China, Japan, and South Korea, and the emergence of well-funded regional startups. Singapore-based Lucence Health, for example, has successfully raised capital to advance liquid biopsy development, and MiRXES raised USD 50 million in 2023 to expand its multi-cancer early detection platform. Government initiatives across the region supporting early cancer detection programs are also pushing institutional procurement.

COMPETITIVE LANDSCAPE
The liquid biopsy market features more than 160 active manufacturers, making it a well-fragmented competitive environment rather than one dominated by a small cluster of incumbents. Key players identified in the report include Amoy Diagnostics, ArcherDX, Biocartis, CellSearch, CellMax Life, Datar Cancer Genetics, DiaCarta, EONE-DIAGNOMICS, Exosome Diagnostics, GeneCast Biotechnology, Integrated DNA Technologies, Lucence, MDNA Life Sciences, Miltenyi Biotec, NeoGenomics, OncoDNA, QIAGEN, Personal Genome Diagnostics, ScreenCell, Tecan, and Thermo Fisher Scientific, among others.

Competition centers on two primary battlegrounds: breadth of biomarker detection (particularly multi-cancer early detection capability) and speed to companion diagnostic approval. Larger players such as Thermo Fisher Scientific and QIAGEN benefit from established laboratory relationships and manufacturing scale, while specialized firms are competing on assay sensitivity and clinical utility data. M&A activity is an active consideration; the report identifies key acquisition targets within its Excel data packs, reflecting an environment where consolidation is a realistic near-term scenario.

Browse Full Report Description + Research Methodology + Table of Content + Infographics here:
https://www.rootsanalysis.com/reports/liquid-biopsy-and-nicd-market/279.html

Contact Details
Gaurav Chaudhary
Email: Gaurav.chaudhary@rootsanalysis.com or sales@rootsanalysis.com
Website: https://www.rootsanalysis.com

About Roots Analysis
Roots Analysis is a global leader in the pharma / biotech market research. Having worked with over 750 clients worldwide, including Fortune 500 companies, start-ups, academia, venture capitalists and strategic investors for more than a decade, we offer a highly analytical / data-driven perspective to a network of over 450,000 senior industry stakeholders looking for credible market insights. All reports provided by us are structured in a way that enables the reader to develop a thorough perspective on the given subject. Apart from writing reports on identified areas, we provide bespoke research / consulting services dedicated to serve our clients in the best possible way.

This release was published on openPR.